Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Small Cell Lung Carcinoma × talazoparib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 mCRPC 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia 1 Hemangiosarcoma 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Interventions

Etoposide 12 Carboplatin 12 durvalumab 9 PM 01183 8 atezolizumab 6 pembrolizumab 5 Topotecan 5 Specimen Handling 4 Radiosurgery 4 Paclitaxel 4 Nivolumab 4 Ipilimumab 3 Drug Therapy 3 Bevacizumab 3 AMG 757 3 cabozantinib 2 berzosertib 2 Temozolomide 2 Radiotherapy 2 Magnetic Resonance Spectroscopy 2 Cisplatin 2 Biopsy 2 tremelimumab 1 trastuzumab deruxtecan 1 toripalimab 1 tazemetostat 1 talazoparib 1 surufatinib 1 stenoparib 1 sacituzumab govitecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04170946 2026-03-05

Talazoparib

University Health Network, Toronto

Phase 1 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡